Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 20/06/2025 BST			5-day change	1st Jan Change
1,377.00 ^DKK	-1.78%		-7.02%	-7.74%

06-17	Genmab A/S, Q1 2025 Earnings Call, May 08, 2025
06-16	Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	MT

Genmab A/S, Q1 2024 Earnings Call, May 02, 2024

Published on 02/05/2024 at 17:00

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Genmab First Quarter 2024 Conference Call. As a reminder, this conference call is being recorded.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

Genmab A/S, Q1 2025 Earnings Call, May 08, 2025	06-17
Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	06-16	MT
Genmab's Epcoritamab Combination Shows High Response Rates in Cancer Patients	06-16	MT
Genmab A/S Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (L) Eligible for Autologous Stem Cell Transplantation	06-15	CI
Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM	06-09
AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	06-09	MT
GENMAB : Beaten up share price offers an opportunity	06-06
Genmab's Rina-S shows promising efficacy in difficult-to-treat uterine cancer	06-03	FW
Sector Update: Health Care Stocks End Higher Late Afternoon	06-02	MT
Genmab Says New Trial Data Shows 'Encouraging Anti-Tumor Activity' for Rinatabart Sesutecan	06-02	MT
Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial	06-02	CI
RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN	05-30	FW
RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating	05-29	MT
Deutsche Bank lowers target price for Genmab to DKK 1,750 (1,900), reiterates buy recommendation	05-23	FW
Redburn lowers target price for Genmab to DKK 2,700 (2,750), reiterates buy recommendation - BN	05-23	FW
Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association Congress	05-14	CI
UBS lowers target price for Genmab to DKK 2,600 (2,700), reiterates buy recommendation	05-12	FW
GENMAB : Mixed Q1; guidance maintained	05-10
Nordea Bank Upgrades Genmab to Buy	05-09	MT
Nykredit lowers target price for Genmab to DKK 1,750 (2,000), reiterates buy recommendation - BN	05-09	FW
Nordea raises Genmab to buy (hold), target price SEK 2,009	05-09	FW
Goldman Sachs raises target price for Genmab to DKK 1,785 (1,764), reiterates neutral rating - BN	05-09	FW
Carnegie raises target price for Genmab to DKK 2,288 (2,263), reiterates buy recommendation - BN	05-09	FW
Cowen lowers target price for Genmab to DKK 1,360 (1,431), reiterates hold rating - BN	05-09	FW
Genmab Q1 Earnings, Revenue Increase	05-08	MT